Summit Therapeutics (NASDAQ: SMMT) Stock Analysis: Guggenheim Reiterates Buy Amid Ivonescimab Progress
Guggenheim maintained a "Buy" rating for Summit Therapeutics, signaling continued analyst confidence in the company's stock performance . Despite a lowered price target to $38.00 from $40.00 , the new target still indicates significant potential upside from the current trading pr
- Guggenheim maintained a "Buy" rating for Summit Therapeutics, signaling continued analyst confidence in the company's stock performance.
- Despite a lowered price target to $38.00 from $40.00, the new target still indicates significant potential upside from the current trading price of $14.98.
- The positive outlook is driven by strong Q2 2026 earnings data and ongoing progress with ivonescimab, including two approvals in China and 52 global clinical trials.
Summit Therapeutics (NASDAQ: SMMT) is a biopharmaceutical company that develops new medicines. It focuses on its main drug candidate, ivonescimab, which is a PD-1/VEGF bispecific antibody. This type of drug is designed to help the body's immune system fight cancer in two different ways at the same time.
On July 24, 2026, the analyst firm Guggenheim restated its "Buy" rating for Summit Therapeutics. A "Buy" rating is given when an analyst believes a stock's price is likely to increase in the near future. This shows the firm's continued positive view of the company's potential performance.
While Guggenheim kept its "Buy" rating, it lowered its price target for Summit Therapeutics to $38.00 from $40.00. A price target is an analyst's estimate of a stock's future price. When this was announced, the stock was trading at $14.98, meaning the new target still suggests a large potential upside.
This analyst action comes after the company's Q2 2026 earnings call, as highlighted by Seeking Alpha. During the call, executives shared positive data for ivonescimab from four late-stage studies. This has already resulted in two drug approvals for the drug in China, with another application under review there.
As reported by Business Wire, Summit Therapeutics' progress with ivonescimab continues to grow. This is supported by strong results from the HARMONi-6 study. Summit Therapeutics and its partner Akeso have started 52 clinical trials for the drug, with over 4,000 patients receiving it globally.
Originally published by fmp.
View original article
